AI platform-based Fragile X Syndrome therapeutic / Healx - LARVOL DELTA

Healx joins forces with Boehringer Ingelheim to discover new treatment approaches for rare neurological diseases (Yahoo Finance) - "Healx Ltd....today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases....The project will leverage Healx’s comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and pharmacology, to identify potential new indications for assets from Boehringer Ingelheim’s pipeline....The company’s AI-based drug discovery platform (Healnet) has proven success...with potential benefits for Fragile X syndrome, which were not considered for the condition prior to Healx’s involvement."

Licensing / partnership

Healx commits $20m to launch rare treatment accelerator programme; Appoints Dr Bruce Bloom as Chief Collaboration Officer to lead initiative (Cambridge Network) - "Healx...today announces that applications are now being accepted for its Rare Treatment Accelerator (RTA)....Healx intends to invest up to the value of $1 million in AI and drug discovery resources per disease project, out of the total budget of $20 million....The company has been working with a number of patient groups since 2014 including its partnership with the FRAXA Research Foundation to develop new treatments for fragile X syndrome...A clinical study with its drug candidates for this indication is planned for the first quarter of 2020...The deadline for applications is 10 January 2020."

Clinical • Financing • New trial